Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

The emergence and development of glucagon-like Peptide-1 agonists (GLP-1s) is the primary trend of interest in the ...

For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

UPMC cites more people seeking medical care and rising pharmacy costs as reasons for its $371 million operating loss for the first nine months of the year, according to a financial and operating ...

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a ...

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

A new study suggests that popular weight loss drugs may reduce the risk of suicide in adolescents. KYW medical editor Dr. Brian McDonough has more.

New research reveals that popular diabetes and weight-loss drugs may also protect the kidneys. This groundbreaking study, ...

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...